Arun Azad

Arun Azad is an expert in Oncology at Peter MacCallum Cancer Centre (Australia). As of October 2026, ScienceLeadR ranks Arun Azad in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Arun Azad has authored 421 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 8 of them ongoing. SLR score: 2,146 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Urology - Nuclear Medicine - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 8, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026

Source: PubMed

Peter MacCallum Cancer Centre

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 421

Citations

Citations: 12 926 1st author: 73 Last author: 82 Unique author: 6

Main journals

J Clin Oncol 96

Eur Urol 21

Asia Pac J Clin Oncol 16

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial. PMID 42801727 — growth, insulin, docetaxel, somatomedins, neoplasms, prostate, drug therapy, biomarkers, hormones, prostatic neoplasms, therapeutics, prognosis, plasma, chemotherapy	Prostate	2026	0
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. PMID 42586114 — cells, progression-free survival, disease progression, carcinoma, renal cell, drug-related side effects and adverse reactions, therapeutics	Lancet Top journal	2026	3
Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer. PMID 42658786 — research design, genes, recombination, genetic, homologous recombination, neoplasms, prostate, hormones, recombinational dna repair, prostatic neoplasms, therapeutics, mutation	Asia Pac J Clin Oncol	2026	0
Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia. PMID 42629959 — cells, neoplasms, carcinoma, renal cell, immunotherapy, therapeutics	Asia Pac J Clin Oncol	2026	0
Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. PMID 42537005 — neoplasms, prostate, prostate-specific antigen, prostatic neoplasms	J Clin Oncol Top journal	2026	0

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 1

By phase:

Phase 2 8

Phase 3 8

Phase 1/Phase 2 6

Phase 1 2

Phase 2/Phase 3 1

By status:

Completed 11

Active not recruiting 10

Recruiting 3

Unknown 1

By type:

Interventional 25

By Monocentric/Multicentric:

monocentric 3

multicentric2to4 4

multicentric5to9 2

multicentricup10 16

Main Topics

Male Urogenital Diseases 21

Female Urogenital Diseases and Pregnancy Complications 4

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration Sensitive Prostate Cancer Receiving Physician s Choice New Hormonal Agents NCT06120491 — neoplasms, abiraterone acetate, prostate, acetates, prostatic neoplasms, castration, men	Phase 3	Active not recruiting	2023
EValuation of radIOLigand Treatment in mEn With Metastatic Castration resistant Prostate Cancer With 161Tb Tb PSMA I T NCT05521412 — safety, neoplasms, prostate, prostatic neoplasms, castration, therapeutics	Phase 1/Phase 2	Recruiting	2022
Combination of Radium 223 and Lutetium 177 PSMA I T in Men with Metastatic Castration Resistant Prostate Cancer NCT05383079 — neoplasms, prostate, prostatic neoplasms, maximum tolerated dose, castration, men	Phase 1/Phase 2	Active not recruiting	2022
Cabazitaxel in Combination With 177Lu PSMA 617 in Metastatic Castration resistant Prostate Cancer NCT05340374 — cells, mitosis, docetaxel, pharmaceutical preparations, neoplasms, radiopharmaceuticals, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, apoptosis, tissues, microtubules, cell death, chemotherapy, small molecules	Phase 1/Phase 2	Recruiting	2022
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma NCT05024318 — radiotherapy, cells, nephrectomy, kidney, carcinoma, renal cell, carcinoma	Phase 2	Recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice